GLP-1 receptor agonists in diabetes and weight loss: the double-edged sword of innovation and risks.
作者信息
Ilias Ioannis, Zabuliene Lina, Rizzo Manfredi
机构信息
Department of Endocrinology, Hippokration General Hospital, Athens, Greece.
Institute of Clinical Medicine, Faculty of Medicine, Vilnius University, Vilnius, Lithuania.
出版信息
Front Clin Diabetes Healthc. 2025 Jan 9;5:1530811. doi: 10.3389/fcdhc.2024.1530811. eCollection 2024.
Abstract
摘要
相似文献
1
GLP-1 receptor agonists in diabetes and weight loss: the double-edged sword of innovation and risks.
Front Clin Diabetes Healthc. 2025 Jan 9;5:1530811. doi: 10.3389/fcdhc.2024.1530811. eCollection 2024.
2
Semaglutide: Nonarteritic Anterior Ischemic Optic Neuropathy in the FDA adverse event reporting system - A disproportionality analysis.
Obes Res Clin Pract. 2025 Jan-Feb;19(1):77-79. doi: 10.1016/j.orcp.2025.01.011. Epub 2025 Feb 7.
3
Peptide-based GLP-1/glucagon co-agonists: A double-edged sword to combat diabesity.
Med Hypotheses. 2016 Oct;95:5-9. doi: 10.1016/j.mehy.2016.08.005. Epub 2016 Aug 12.
4
The Effect of Semaglutide and GLP-1 RAs on Risk of Nonarteritic Anterior Ischemic Optic Neuropathy.
Am J Ophthalmol. 2025 Jun;274:24-31. doi: 10.1016/j.ajo.2025.02.025. Epub 2025 Feb 25.
5
Real-world evidence on the utilization, clinical and comparative effectiveness, and adverse effects of newer GLP-1RA-based weight-loss therapies.
Diabetes Obes Metab. 2025 Apr;27 Suppl 2(Suppl 2):66-88. doi: 10.1111/dom.16364. Epub 2025 Apr 8.
6
Seven glucagon-like peptide-1 receptor agonists and polyagonists for weight loss in patients with obesity or overweight: an updated systematic review and network meta-analysis of randomized controlled trials.
Metabolism. 2024 Dec;161:156038. doi: 10.1016/j.metabol.2024.156038. Epub 2024 Sep 19.
7
Risk of Nonarteritic Anterior Ischemic Optic Neuropathy in Patients Prescribed Semaglutide.
JAMA Ophthalmol. 2024 Aug 1;142(8):732-739. doi: 10.1001/jamaophthalmol.2024.2296.
8
Association between Semaglutide and Nonarteritic Anterior Ischemic Optic Neuropathy: A Multinational Population-Based Study.
Ophthalmology. 2025 Apr;132(4):381-388. doi: 10.1016/j.ophtha.2024.10.030. Epub 2024 Nov 2.
9
Semaglutide and Nonarteritic Anterior Ischemic Optic Neuropathy.
JAMA Ophthalmol. 2025 Apr 1;143(4):304-314. doi: 10.1001/jamaophthalmol.2024.6555.
10
Weight Loss and Maintenance Related to the Mechanism of Action of Glucagon-Like Peptide 1 Receptor Agonists.
Adv Ther. 2021 Jun;38(6):2821-2839. doi: 10.1007/s12325-021-01710-0. Epub 2021 May 11.
引用本文的文献
1
Prevalence and associated factors of eating disorders among metabolic bariatric surgery patients in Egypt.
J Eat Disord. 2025 Aug 25;13(1):182. doi: 10.1186/s40337-025-01373-0.
2
Exploring the Protective Effects of Traditional Antidiabetic Medications and Novel Antihyperglycemic Agents in Diabetic Rodent Models.
Pharmaceuticals (Basel). 2025 May 1;18(5):670. doi: 10.3390/ph18050670.
3
The widening landscape of synthetic incretin treatment: possible association of ischaemic optic neuropathy risk and the need for a cautious approach.
Eye (Lond). 2025 Jun;39(8):1648-1649. doi: 10.1038/s41433-025-03776-4. Epub 2025 Apr 3.
本文引用的文献
1
Sweetening the deal: an infodemiological study of worldwide interest in semaglutide using Google Trends extended for health application programming interface.
BMC Glob Public Health. 2024 Sep 17;2(1):63. doi: 10.1186/s44263-024-00095-w.
2
Role of glucagon-like peptide-1 receptor agonists in Alzheimer's disease and Parkinson's disease.
J Biomed Sci. 2024 Nov 5;31(1):102. doi: 10.1186/s12929-024-01090-x.
3
Incretin Mimetics as Potential Disease Modifying Treatment for Alzheimer's Disease.
J Alzheimers Dis. 2024;101(s1):S357-S370. doi: 10.3233/JAD-240730.
4
Strategies for minimizing muscle loss during use of incretin-mimetic drugs for treatment of obesity.
Obes Rev. 2025 Jan;26(1):e13841. doi: 10.1111/obr.13841. Epub 2024 Sep 19.
5
Glucagon-like peptide-1 receptor agonists and risk of gastrointestinal cancers: A systematic review and meta-analysis of randomized controlled trials.
Pharmacol Res. 2024 Oct;208:107401. doi: 10.1016/j.phrs.2024.107401. Epub 2024 Sep 7.
6
A review of serious adverse events linked with GLP-1 agonists in type 2 diabetes mellitus and obesity treatment.
Pharmacol Rep. 2024 Oct;76(5):981-990. doi: 10.1007/s43440-024-00629-x. Epub 2024 Aug 2.
7
Modern Management of Cardiometabolic Continuum: From Overweight/Obesity to Prediabetes/Type 2 Diabetes Mellitus. Recommendations from the Eastern and Southern Europe Diabetes and Obesity Expert Group.
Diabetes Ther. 2024 Sep;15(9):1865-1892. doi: 10.1007/s13300-024-01615-5. Epub 2024 Jul 11.
8
Incretin mimetics and acute pancreatitis: enemy or innocent bystander?
Curr Opin Gastroenterol. 2024 Sep 1;40(5):404-412. doi: 10.1097/MOG.0000000000001057. Epub 2024 Jul 4.
9
Risk of Nonarteritic Anterior Ischemic Optic Neuropathy in Patients Prescribed Semaglutide.
JAMA Ophthalmol. 2024 Aug 1;142(8):732-739. doi: 10.1001/jamaophthalmol.2024.2296.
10
Role of gut-liver axis and glucagon-like peptide-1 receptor agonists in the treatment of metabolic dysfunction-associated fatty liver disease.
World J Gastroenterol. 2024 Jun 21;30(23):2964-2980. doi: 10.3748/wjg.v30.i23.2964.
Zotero 插件